| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:P163-0892
CAS:1574576-45-6
Package:25mg/RMB 14900;100mg/RMB 24625;50mg/RMB 19420
|
Thieno[3,2-b]pyridine-6-carboxamide, N-butyl-4,5-dihydro-7-hydroxy-5-oxo-4-(phenylmethyl)- manufacturers
- P163-0892
-
- $2140.00
-
2026-05-11
- CAS:1574576-45-6
- Purity:
- Supply Ability: 10g
|
| | Thieno[3,2-b]pyridine-6-carboxamide, N-butyl-4,5-dihydro-7-hydroxy-5-oxo-4-(phenylmethyl)- Basic information |
| | Thieno[3,2-b]pyridine-6-carboxamide, N-butyl-4,5-dihydro-7-hydroxy-5-oxo-4-(phenylmethyl)- Chemical Properties |
| Boiling point | 567.0±50.0 °C(Predicted) | | density | 1.332±0.06 g/cm3(Predicted) | | pka | 4.50±1.00(Predicted) |
| | Thieno[3,2-b]pyridine-6-carboxamide, N-butyl-4,5-dihydro-7-hydroxy-5-oxo-4-(phenylmethyl)- Usage And Synthesis |
| Uses | P163-0892 is a potent and selective antifungal agent against Cryptococcus species. P163-0892 is predicted to show medium BBB penetration[1]. | | in vivo | P163-0892 (10 mg/kg; 5 days) significantly extends the survival of larvae infected with either C. neoformans or C. gattii[1]. | Animal Model: | Wax moth larva infected with C. neoformans H99 or C. gattii WM178[1] | | Dosage: | 10 mg/kg | | Administration: | 5 days | | Result: | Increased the survival rate of larvae. |
| Animal Model: | Male Sprague–Dawley rats weighing 200–250 g[1] | | Dosage: | 2 mg/kg or 5 mg/kg | | Administration: | Intravenous or oral administration (Pharmacokinetic Analysis) | | Result: | Pharmacokinetic Parameters of P163-0892a[1]
| route | dose (mg/kg) | T1/2 (h) | Tmax (h) | AUC0-inf (hng/mL) | Cl (mL/h/kg) | MRT0-t (h) | Vdss (L/kg) | BA (%) | | iv | 2 mg/kg | 7.61 | | 749 | 172 | 2.63 | 7.12 | | | po | 5 mg/kg | 15.3 | 3.17 | NR | | 3.83 | NR | 0.8 |
aAbbreviations: iv, intravenous; po, per os; T1/2, half-life elimination in hours; Tmax, time of maximal concentration in hours; AUC, area under the curve; Cl, clearance; MRT, mean residence time; Vdss, volume of distribution at the steady state; BA, bioavailability; NR, not reportable; n = 3.
|
| | References | [1] Li L, et al. Discovery of Novel 7-Hydroxy-5-oxo-4,5-dihydrothieno[3,2-b]pyridine-6-carboxamide Derivatives with Potent and Selective Antifungal Activity against Cryptococcus Species. J Med Chem. 2022 Aug 3. DOI:10.1021/acs.jmedchem.2c00794 |
| | Thieno[3,2-b]pyridine-6-carboxamide, N-butyl-4,5-dihydro-7-hydroxy-5-oxo-4-(phenylmethyl)- Preparation Products And Raw materials |
|